Welcome to our dedicated page for Lexeo Therapeutics news (Ticker: LXEO), a resource for investors and traders seeking the latest updates and insights on Lexeo Therapeutics stock.
Lexeo Therapeutics, Inc. develops clinical-stage genetic medicines for cardiovascular diseases, with company updates centered on AAV-based gene therapy candidates and related cardiac delivery technology. Its portfolio includes LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for PKP2-associated arrhythmogenic cardiomyopathy.
Recurring developments include clinical data from cardiac gene therapy studies, FDA and CMC engagement, manufacturing work involving an optimized Sf9-baculovirus AAV platform, research collaborations for targeted cardiac delivery, quarterly financial results, conference presentations, and leadership or board changes tied to the company’s cardiovascular medicine focus.
Lexeo Therapeutics (Nasdaq:LXEO) will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026, at 2:35 p.m. ET in New York.
The event will be webcast live with a replay available on Lexeo’s investor website.
Lexeo Therapeutics (Nasdaq:LXEO) reported Q1 2026 updates and financials. LX2006 interim data in Friedreich ataxia showed statistically significant mean mFARS improvements versus a propensity-matched control cohort and remained generally well tolerated with no Grade 3+ SAEs.
The SUNRISE‑FA 2 pivotal trial protocol and SAP were submitted to the FDA, with feedback and trial initiation expected in Q2 2026. LX2020 in PKP2-ACM showed positive interim data and favorable tolerability. Cash, cash equivalents and investments totaled $227.6 million, expected to fund operations into 2028, while net loss narrowed to $20.2 million.
Lexeo Therapeutics (Nasdaq: LXEO) will present new preclinical and early clinical data at the 29th ASGCT Annual Meeting, May 11–15, 2026 in Boston. Presentations cover cardiac gene therapy programs (including TNNI3 cardiomyopathy and AAVrh.10hFXN for Friedreich ataxia), Sf9‑baculovirus AAV manufacturing comparability and scale‑up, and sequencing in release testing.
Multiple oral and poster sessions are scheduled, including oral talks May 12 and May 15 and poster sessions May 13–14.
Lexeo Therapeutics (NASDAQ: LXEO) reported Q4 and full-year 2025 results and provided program updates on its cardiac genetic-medicine pipeline.
Key developments include FDA analytical comparability approval for LX2006 manufacturing, submission of the SUNRISE-FA 2 protocol/SAP, positive Phase I/II interim data for LX2006 and LX2020, a research collaboration with Johnson & Johnson, a $154 million October 2025 equity financing, and $246.6 million in cash expected to fund operations into 2028.
Lexeo Therapeutics (Nasdaq: LXEO) will participate in a fireside chat at the Leerink Global Healthcare Conference on March 10, 2026 at 10:00 a.m. ET in Miami, FL.
The presentation will be webcast live via the company's Investors & News & Events page, with a replay available on the Lexeo website after the session.
Lexeo Therapeutics (NASDAQ: LXEO) said members of management will present at two investor conferences in February 2026: a Guggenheim Emerging Outlook: Biotech Summit fireside chat on Feb 12, 2026 at 12:30 p.m. ET in New York and an Oppenheimer Healthcare Life Sciences fireside chat on Feb 26, 2026 at 10:40 a.m. ET (virtual).
Both events will be webcast live and replays will be available under the News & Events tab in the Investors section of the company website.
Lexeo Therapeutics (Nasdaq: LXEO) announced multiple senior leadership appointments and an update to its strategic partnership for cardiac RNA therapeutics on January 27, 2026. Key hires include Narinder Bhalla, MD as Chief Medical Officer, José Manuel Otero, PhD as Chief Operating Officer, and new cardiology development leads Hayes Dansky, MD and Greg Aubert, MD, PhD. Eric Adler, MD will become CEO of Myoventive, a cardiac precision medicines company co-founded by Lexeo and partners to develop a novel non-viral RNA platform for genetic cardiac diseases. The appointments are presented as strengthening late-stage clinical and commercial execution while maintaining discovery and early cardiac development.
Lexeo Therapeutics (NASDAQ: LXEO) reported interim Phase I/II HEROIC-PKP2 data for LX2020 in PKP2-associated arrhythmogenic cardiomyopathy on Jan 12, 2026.
Ten participants dosed (low 2x1013 vg/kg, high 6x1013 vg/kg). LX2020 was generally well tolerated, no clinically significant complement activation, and all LFT elevations resolved with protocol immunosuppression. In biopsies (n=7) mean PKP2 protein increased +93% (low dose) and +162% (high dose). In participants with ≥6 months follow-up (n=8) NSVT improved 22% and PVCs improved 14% in high-dose cohorts. Enrollment complete; 12-month high-dose data due Q4 2026.
Lexeo Therapeutics (NASDAQ: LXEO) announced a research collaboration with Johnson & Johnson on January 8, 2026 to investigate localized cardiac delivery of AAV gene therapy using Impella heart pump technology. The agreement targets preclinical development of a cardiac gene therapy route that concentrates AAV delivery to the heart, with the stated goals of reducing required AAV doses, improving safety, and maximizing transgene expression and clinical efficacy. The program will evaluate cutting‑edge, localized routes of administration combined with direct cardiac unloading to enhance myocardial perfusion.
Lexeo Therapeutics (NASDAQ: LXEO) announced that CEO R. Nolan Townsend will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 7:30 AM PT in San Francisco.
The presentation will be webcast live on the company's investor website under the News & Events tab, and a replay will be posted on the website after the presentation.